Therapeutic Asset Ratings
603 results matching 1 filter
129,767 assets · 8,707 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
Avutometinib
Refractory Malignant Neoplasm
Memorial Sloan Kettering Cancer Center
P1
C
(39)
azd1390
Metastatic Malignant Neoplasm
Memorial Sloan Kettering Cancer Center
P1
C
(39)
BMS-986504
Urothelial Carcinoma
Memorial Sloan Kettering Cancer Center
P1
C
(39)
crd3874
Sarcoma
Memorial Sloan Kettering Cancer Center
P1
C
(39)
Egfrt/19-28Z/Il-12 Car T-Lymphocytes
Non-Hodgkin Lymphoma
Memorial Sloan Kettering Cancer Center
P1
C
(39)
hu5B1-TCO
Malignant Pancreatic Neoplasm
Memorial Sloan Kettering Cancer Center
P1
C
(39)
ln-144
Metastatic Melanoma
Memorial Sloan Kettering Cancer Center
P1
C
(39)
m28z1xxpd1dnr car
Esophageal Adenocarcinoma
Memorial Sloan Kettering Cancer Center
P1
C
(39)
mq719
Cancer
Memorial Sloan Kettering Cancer Center
P1
C
(39)
mq719
Metastatic Malignant Neoplasm
Memorial Sloan Kettering Cancer Center
P1
C
(39)
mq719
Refractory Malignant Neoplasm
Memorial Sloan Kettering Cancer Center
P1
C
(39)
Tisagenlecleucel
Marginal Zone Lymphoma
Memorial Sloan Kettering Cancer Center
P1
C
(39)
VIPIVOTIDE TETRAXETAN
Glioma
Memorial Sloan Kettering Cancer Center
P1
C
(39)
1,4,7,10-TETRAAZACYCLODODECANE-1,4,7-TRIACETIC ACID, 10-(2-(((4-(((3-((2R,5S,8S,14R)-5-(3-((AMINOIMINOMETHYL)AMINO)PROPYL)-14-((4-HYDROXYPHENYL)METHYL)-1-METHYL-8-(2-NAPHTHALENYLMETHYL)-3,6,9,12,15-PENTAOXO-1,4,7,10,13-PENTAAZACYCLOPENTADEC-2-YL)PROPYL)AMINO)CARBONYL)PHENYL)METHYL)AMINO)-2-OXOETHYL)-
Erdheim-Chester Disease
Memorial Sloan Kettering Cancer Center
Early P1
C
(39)
1,4,7,10-TETRAAZACYCLODODECANE-1,4,7-TRIACETIC ACID, 10-(2-(((4-(((3-((2R,5S,8S,14R)-5-(3-((AMINOIMINOMETHYL)AMINO)PROPYL)-14-((4-HYDROXYPHENYL)METHYL)-1-METHYL-8-(2-NAPHTHALENYLMETHYL)-3,6,9,12,15-PENTAOXO-1,4,7,10,13-PENTAAZACYCLOPENTADEC-2-YL)PROPYL)AMINO)CARBONYL)PHENYL)METHYL)AMINO)-2-OXOETHYL)-
Histiocytic Neoplasms
Memorial Sloan Kettering Cancer Center
Early P1
C
(39)
1,4,7,10-TETRAAZACYCLODODECANE-1,4,7-TRIACETIC ACID, 10-(2-(((4-(((3-((2R,5S,8S,14R)-5-(3-((AMINOIMINOMETHYL)AMINO)PROPYL)-14-((4-HYDROXYPHENYL)METHYL)-1-METHYL-8-(2-NAPHTHALENYLMETHYL)-3,6,9,12,15-PENTAOXO-1,4,7,10,13-PENTAAZACYCLOPENTADEC-2-YL)PROPYL)AMINO)CARBONYL)PHENYL)METHYL)AMINO)-2-OXOETHYL)-
Sinus Histiocytosis With Massive Lymphadenopathy
Memorial Sloan Kettering Cancer Center
Early P1
C
(39)
Chimeric Antigen Receptor Modified T Cells Infusion
DLBCL Activated B-Cell Type
Memorial Sloan Kettering Cancer Center
Early P1
C
(39)
Chimeric Antigen Receptor Modified T Cells Infusion
Dlbcl-Ci
Memorial Sloan Kettering Cancer Center
Early P1
C
(39)
Chimeric Antigen Receptor Modified T Cells Infusion
DLBCL Germinal Center B-Cell Type
Memorial Sloan Kettering Cancer Center
Early P1
C
(39)
Chimeric Antigen Receptor Modified T Cells Infusion
HGBL
Memorial Sloan Kettering Cancer Center
Early P1
C
(39)
Cyclophosphamide
Identified by NGS, PCR or IHC
Memorial Sloan Kettering Cancer Center
Early P1
C
(39)
DIHYDROTESTOSTERONE
Female Breast Carcinoma
Memorial Sloan Kettering Cancer Center
Early P1
C
(39)
Epirubicin
Identified by NGS, PCR or IHC
Memorial Sloan Kettering Cancer Center
Early P1
C
(39)
MONOCLONAL ANTIBODY BC8
B ALL
Memorial Sloan Kettering Cancer Center
Early P1
C
(39)
MONOCLONAL ANTIBODY BC8
B-Cell Acute Lymphoblastic Leukemia
Memorial Sloan Kettering Cancer Center
Early P1
C
(39)
Showing 501 to 525 of 603 assets
Previous
Page 21 of 25
Next
